OC16.01: Congenital anomalies associated with low‐dose aspirin exposure during the embryonic versus fetal periods: a secondary analysis of the ASPIRIN trial
Year: 2024
Type: conference-abstract
Abstract: To determine if there is a difference in the incidence of congenital anomalies based on the gestational age at which low-dose aspirin (LDA) is initiated (embryonic period vs. fetal period). This was a secondary analysis of the ASPIRIN trial in which nulliparous women were randomised to LDA (81mg daily) or placebo between 6+0/7 and 13+6/7 weeks of gestation and continued until 36+7/7 weeks of gestation or delivery. The primary outcome of this study was the incidence of preterm birth; secondary endpoints included maternal, fetal, and neonatal outcomes. A subgroup analysis was performed to assess if there is a difference regarding congenital anomalies among participants who started LDA before or after 9.0 weeks of gestation (embryonic or fetal periods). Logistic regression models assessed the interaction between the above mentioned subgroup and the exposure. Results are presented with a P-value for interaction and corresponding odds ratios (ORs). There was no evidence of heterogeneity in the incidence of congenital anomalies in embryonic vs. fetal subgroups (overall OR 0.89, 95% confidence interval [CI] 0.55, 1.43; <9 weeks OR 1.48, 95% CI 0.68, 3.19; ≥9 weeks OR 0.63, 95% CI 0.34, 1.19), P-value for the interaction 0.095, see figure 1). In this secondary analysis of the ASPIRIN trial, there was no significant heterogeneity in the incidence of congenital anomalies between patients who started LDA consumption before or after 9.0 weeks of gestation. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
DOI: 10.1002/uog.27829
Institutions: Universidad Panamericana, Instituto Nacional de Perinatología
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402360633